semaglutide biomarkers alzheimer GLP-1RA Alzheimer's hopes dashed after Novo Nordisk's miss Semaglutide fails to slow progression

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM et al

10.1016/j.freeradbiomed.2019.06.019 Summary Keywords obesity, semaglutide, gut microbiota, metabolomics, fecal microbiota transplantation Citation Sun L, Shang B, Lv S, Liu G, Wu Q and Geng Y (2025) Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice

Brand-name medications are not foregrounded, and no guarantees are made about which options may be available

Discover Our Peptide Portfolio In 2023, the FDA reviewed several peptides nominated for compounding and placed many on the 503A Category 2 list.[3] Then in 2024, the agency cited limited clinical safety data, along with concerns about immunogenicity (how the immune system might respond) and dosing variability.[4] It was a precautionary decision, and precaution is an important part of regulatory oversight